![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Roche Gains Rights to Eye Drug From Lineage Cell Therapeutics
Roche Gains Rights to Eye Drug From Lineage Cell Therapeutics
Roche’s Genentech subsidiary has struck a deal with Lineage Cell Therapeutics to license and develop the latter’s investigational eye drug — a retinal pigment epithelium (RPE) therapy being prepped for a form of advanced dry age-related macular degeneration.
Under the deal, Roche will pay Lineage $50 million upfront and potentially a further $620 million in milestones-based payments as well as royalties on sales.
Lineage is currently assessing the drug in an early-phase study, but Roche will handle all future clinical development for the product.
Upcoming Events
-
21Oct